Philadelphia, PANCT06699836Now EnrollingIRB Ready

Colorectal Cancer Clinical Trial in Philadelphia, PA

Access cutting-edge colorectal cancer treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by CytoDyn, Inc.

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions...

Expert Care in Philadelphia

Access colorectal cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related colorectal cancer treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this colorectal cancer clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Colorectal Cancer Study in Philadelphia

This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with CCR5+, MSS, mCRC who have progressed on prior treatment before participating in the study. The main questions this study aims to answer are: 1. Can leronlimab, in combination with standard of care therapies trifluridine and tipiracil+ be

Sponsor: CytoDyn, Inc.

Who Can Participate

Inclusion Criteria

Male or female subjects age ≥ 18 years with a history of treated colorectal cancer with unresectable metastases of the primary colorectal cancer to other organs. 2. If HIV-1 positive, viral load must be \< 50 copies/ml and participant must be on stable ART for at least 3 months. 3. Demonstrate positive tumor expression of CCR5 by IHC. 4. Adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. 5. Histologically confirmed for microsatellite stable MSS colorectal cancer by PCR, Immunohistochemistry (IHC) or Next-generation sequencing (NGS). 6. Have measurable disease per RECIST 1.1 7. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 8. Expected survival of at least three months 9. No anti-cancer treatment within the last four weeks or at l

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT06699836) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Colorectal Cancer Treatment Options in Philadelphia, PA

If you're searching for colorectal cancer treatment options in Philadelphia, PA, this clinical trial (NCT06699836) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced colorectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all colorectal cancer clinical trials near you to find additional studies recruiting in your area.

More Colorectal Cancer Trials in Philadelphia, PA

See all colorectal cancer clinical trials recruiting in Philadelphia — not just this study.

Browse Colorectal Cancer Trials in Philadelphia →

Browse More Trials by Condition

Colorectal Cancer TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA